Care Pharmaceuticals

carepharma.com.au

Care Pharmaceuticals was established in Australia in 1986 (formerly known as Paedpharm Pty Ltd) and is now part of Prestige Brands Holdings Inc (Prestige acquired Care in July 2013). We focus on product innovation and quality in over-the-counter healthcare to better improve the lives of our customers and their world. For generations, our trusted brands have helped consumers care for themselves and their loved ones. Our brands include Hydralyte, FESS Nasal Sprays and Murine eye care.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

VIGILANZ LAUNCHES COVID QUICK START SOFTWARE THAT GIVES HOSPITALS CUSTOMIZABLE REAL-TIME ALERTS AND REPORTS TO MANAGE VIRAL OUTBREAKS

Prnewswire | May 21, 2020

news image

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Read More

Pharmacy Market

TC BIOPHARM BEGINS DOSING PHASE 2B CLINICAL STUDY EVALUATING ITS LEAD COMPOUND, OMNIMMUNE®, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

TC BioPharm | November 23, 2022

news image

TC Biopharm a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia. The initial 5 patients in the trial are deemed a "safety cohort", spaced two weeks apart with safety review by an oversight board to confirm no drug related toxic...

Read More

Business Insights

SAUDI MINISTRY OF INVESTMENT AND INSILICO MEDICINE SIGN AGREEMENT TO EXPAND REGION’S BIOTECHNOLOGY CAPABILITIES

Insilico Medicine | September 15, 2022

news image

Saudi Arabia’s Ministry of Investment and clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine have signed a memorandum of understanding (MoU) to support the development of a robust AI-driven biotech industry in the Kingdom. The agreement was signed during the Global AI Summit, held from the 13th through the 15th of September in Riyadh, which featured over 200 speakers representing 90 countries discussing the future of AI, including Insilico Medicine ...

Read More

COVID-19: VACCINE AND DRUG DEVELOPMENT UPDATES

BioTechniques | April 08, 2020

news image

Providing the latest updates in the understanding of coronavirus, drug development and clinical trials for a vaccine for COVID-19. A study seeking to determine which of the lung and bronchi cells are targets for SARS-CoV-2 has been recently published in The EMBO Journal, suggesting the target is progenitor cells that usually develop into respiratory tract cells lined with cilia. This follows previous research that had demonstrated that the virus spike protein attaches to the ACE2 receptor on cel...

Read More
news image

VIGILANZ LAUNCHES COVID QUICK START SOFTWARE THAT GIVES HOSPITALS CUSTOMIZABLE REAL-TIME ALERTS AND REPORTS TO MANAGE VIRAL OUTBREAKS

Prnewswire | May 21, 2020

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Read More

news image

Pharmacy Market

TC BIOPHARM BEGINS DOSING PHASE 2B CLINICAL STUDY EVALUATING ITS LEAD COMPOUND, OMNIMMUNE®, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

TC BioPharm | November 23, 2022

TC Biopharm a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia. The initial 5 patients in the trial are deemed a "safety cohort", spaced two weeks apart with safety review by an oversight board to confirm no drug related toxic...

Read More
news image

Business Insights

SAUDI MINISTRY OF INVESTMENT AND INSILICO MEDICINE SIGN AGREEMENT TO EXPAND REGION’S BIOTECHNOLOGY CAPABILITIES

Insilico Medicine | September 15, 2022

Saudi Arabia’s Ministry of Investment and clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine have signed a memorandum of understanding (MoU) to support the development of a robust AI-driven biotech industry in the Kingdom. The agreement was signed during the Global AI Summit, held from the 13th through the 15th of September in Riyadh, which featured over 200 speakers representing 90 countries discussing the future of AI, including Insilico Medicine ...

Read More
news image

COVID-19: VACCINE AND DRUG DEVELOPMENT UPDATES

BioTechniques | April 08, 2020

Providing the latest updates in the understanding of coronavirus, drug development and clinical trials for a vaccine for COVID-19. A study seeking to determine which of the lung and bronchi cells are targets for SARS-CoV-2 has been recently published in The EMBO Journal, suggesting the target is progenitor cells that usually develop into respiratory tract cells lined with cilia. This follows previous research that had demonstrated that the virus spike protein attaches to the ACE2 receptor on cel...

Read More